Cover Image
市場調查報告書

Bioversys AG的產品平台分析

Bioversys AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 319968
出版日期 內容資訊 英文 20 Pages
訂單完成後即時交付
價格
Back to Top
Bioversys AG的產品平台分析 Bioversys AG - Product Pipeline Review - 2015
出版日期: 2015年05月29日 內容資訊: 英文 20 Pages
簡介

Bioversys AG是總公司設置於瑞士的生物製藥企業,正在進行將病原菌的抗藥性弱化,讓抗生劑重新有效之低分子藥的研究開發。

本報告提供Bioversys AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,加上最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

目錄

Bioversys AG的基本資料

  • Bioversys AG概要
  • 主要資訊
  • 企業資料

Bioversys AG:R&D概要

  • 主要的治療範圍

Bioversys AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Bioversys AG:開發中產品概況

  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發階段的產品/聯合治療模式

Bioversys AG:藥物簡介

  • BV-6481
  • Small Molecules for Tuberculosis
  • BVNC-1
  • BVNC-2
  • BVTB-2
  • Small Molecules for Multi-Drug Resistant Bacterial Infections

Bioversys AG:開發平台分析

  • 各分子類型

Bioversys AG:開發暫停中的計劃

Bioversys AG:總公司和子公司的所在地

  • 總公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07104CDB

Summary

Global Markets Direct's, 'Bioversys AG - Product Pipeline Review - 2015', provides an overview of the Bioversys AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Bioversys AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Bioversys AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Bioversys AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Bioversys AG's pipeline products

Reasons to buy

  • Evaluate Bioversys AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Bioversys AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Bioversys AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Bioversys AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Bioversys AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Bioversys AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Bioversys AG Snapshot
    • Bioversys AG Overview
    • Key Information
    • Key Facts
  • Bioversys AG - Research and Development Overview
    • Key Therapeutic Areas
  • Bioversys AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Bioversys AG - Pipeline Products Glance
    • Bioversys AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Bioversys AG - Drug Profiles
    • BV-6481
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Tuberculosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BVNC-1
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BVNC-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BVTB-2
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Multi-Drug Resistant Bacterial Infections
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Bioversys AG - Pipeline Analysis
  • Bioversys AG - Pipeline Products by Molecule Type
  • Bioversys AG - Dormant Projects
  • Bioversys AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Bioversys AG, Key Information
  • Bioversys AG, Key Facts
  • Bioversys AG - Pipeline by Indication, 2015
  • Bioversys AG - Pipeline by Stage of Development, 2015
  • Bioversys AG - Monotherapy Products in Pipeline, 2015
  • Bioversys AG - Preclinical, 2015
  • Bioversys AG - Discovery, 2015
  • Bioversys AG - Pipeline by Molecule Type, 2015
  • Bioversys AG - Dormant Developmental Projects,2015

List of Figures

  • Bioversys AG - Pipeline by Top 10 Indication, 2015
  • Bioversys AG - Pipeline by Stage of Development, 2015
  • Bioversys AG - Monotherapy Products in Pipeline, 2015
  • Bioversys AG - Pipeline by Top 10 Molecule Type, 2015
Back to Top